GPRC5C (G Protein-Coupled Receptor Class C Group 5 Member C)

Enrichment analysis implicated key biological processes, including kinase signaling, cell cycle regulation, and microRNA pathways involved in apoptosis and oncogenesis. This study reveals novel differential DNA methylation patterns associated with EOS in the Chinese population and identifies key biological pathways potentially underlying its pathogenesis.

MLH1 and GPRC5C have divergent expressions with an inverse correlation and function as promising novel prognostic indicators in resectable HCC.

In animal models and human PDAC tissues, tumoral GPRC5C expression, negatively associated with MLH1 expressions, was positively correlated with histological grade, vessel invasion, and poor cancer-specific survival. In conclusion, MLH1 inhibits the metastatic potential of PDAC via down-regulation of GPRC5C.

MET fusions are a rare, but potentially actionable, genomic alteration. Our study provides a comprehensive characterization of MET fusions in NSCLC, revealing their diverse fusion partners and co-occurring genomic alterations. Further research is warranted to elucidate the clinical implications of MET fusions in the treatment of various types of cancer, including lung cancer.